Donald Scott McLeod, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 15 | 2022 | 2282 | 2.370 |
Why?
|
| Carcinoma, Papillary | 3 | 2020 | 783 | 0.960 |
Why?
|
| Iodine Radioisotopes | 5 | 2022 | 1032 | 0.790 |
Why?
|
| Hyperthyroidism | 1 | 2022 | 295 | 0.710 |
Why?
|
| Thyroid Diseases | 1 | 2022 | 379 | 0.650 |
Why?
|
| Hypothyroidism | 1 | 2022 | 658 | 0.580 |
Why?
|
| Thyrotoxicosis | 1 | 2015 | 82 | 0.500 |
Why?
|
| Vitamin D | 10 | 2023 | 3224 | 0.490 |
Why?
|
| Mexican Americans | 1 | 2015 | 165 | 0.480 |
Why?
|
| Autoimmunity | 1 | 2022 | 1350 | 0.480 |
Why?
|
| Thyrotropin | 2 | 2015 | 849 | 0.470 |
Why?
|
| Australia | 12 | 2023 | 1167 | 0.460 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 2015 | 331 | 0.450 |
Why?
|
| Hypercalcemia | 1 | 2015 | 409 | 0.420 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2015 | 324 | 0.400 |
Why?
|
| Dietary Supplements | 9 | 2023 | 3296 | 0.390 |
Why?
|
| Vitamins | 8 | 2023 | 1623 | 0.320 |
Why?
|
| Thyroid Gland | 1 | 2015 | 1173 | 0.320 |
Why?
|
| Ultraviolet Rays | 2 | 2022 | 1060 | 0.300 |
Why?
|
| Queensland | 6 | 2021 | 37 | 0.270 |
Why?
|
| Antithyroid Agents | 2 | 2016 | 70 | 0.270 |
Why?
|
| Vitamin D Deficiency | 3 | 2022 | 1343 | 0.230 |
Why?
|
| Trophoblasts | 2 | 2022 | 215 | 0.220 |
Why?
|
| Thyroidectomy | 2 | 2019 | 879 | 0.210 |
Why?
|
| Cholecalciferol | 5 | 2023 | 535 | 0.190 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2021 | 2043 | 0.190 |
Why?
|
| Prealbumin | 2 | 2022 | 210 | 0.190 |
Why?
|
| Combat Disorders | 1 | 2001 | 302 | 0.170 |
Why?
|
| Diseases in Twins | 1 | 2001 | 449 | 0.170 |
Why?
|
| Thyroxine | 1 | 2022 | 667 | 0.160 |
Why?
|
| Scavenger Receptors, Class B | 1 | 2018 | 81 | 0.160 |
Why?
|
| Receptors, Lipoprotein | 1 | 2018 | 81 | 0.160 |
Why?
|
| Lymphatic Metastasis | 3 | 2020 | 2924 | 0.150 |
Why?
|
| Incidence | 7 | 2022 | 20952 | 0.150 |
Why?
|
| Methimazole | 1 | 2015 | 41 | 0.130 |
Why?
|
| Propylthiouracil | 1 | 2015 | 69 | 0.130 |
Why?
|
| Hysterectomy | 1 | 2021 | 927 | 0.130 |
Why?
|
| Graves Disease | 1 | 2016 | 242 | 0.120 |
Why?
|
| Environment | 1 | 2001 | 1123 | 0.120 |
Why?
|
| Neoplasms | 3 | 2022 | 21696 | 0.120 |
Why?
|
| Humans | 36 | 2023 | 744366 | 0.120 |
Why?
|
| Aged | 18 | 2023 | 163288 | 0.120 |
Why?
|
| Antibodies | 1 | 2022 | 2460 | 0.120 |
Why?
|
| Lipoproteins, HDL | 1 | 2018 | 638 | 0.110 |
Why?
|
| Patient Preference | 1 | 2021 | 889 | 0.110 |
Why?
|
| Accidental Falls | 1 | 2021 | 1062 | 0.110 |
Why?
|
| Respiratory Tract Infections | 1 | 2021 | 961 | 0.110 |
Why?
|
| Placenta | 2 | 2022 | 1699 | 0.110 |
Why?
|
| Amyloidosis | 1 | 2019 | 796 | 0.100 |
Why?
|
| Double-Blind Method | 5 | 2023 | 12025 | 0.100 |
Why?
|
| Terminology as Topic | 1 | 2019 | 1547 | 0.100 |
Why?
|
| Case-Control Studies | 4 | 2022 | 21748 | 0.100 |
Why?
|
| Diabetes, Gestational | 1 | 2020 | 1184 | 0.100 |
Why?
|
| Alcoholism | 1 | 2001 | 1906 | 0.090 |
Why?
|
| Adult | 14 | 2022 | 214052 | 0.090 |
Why?
|
| Female | 18 | 2023 | 380193 | 0.080 |
Why?
|
| Age of Onset | 1 | 2015 | 3270 | 0.080 |
Why?
|
| Nutrition Surveys | 1 | 2015 | 1660 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2021 | 23336 | 0.080 |
Why?
|
| Logistic Models | 3 | 2021 | 13409 | 0.080 |
Why?
|
| Survival Rate | 3 | 2019 | 12788 | 0.080 |
Why?
|
| Male | 15 | 2023 | 350115 | 0.080 |
Why?
|
| Carcinoma | 1 | 2019 | 2375 | 0.070 |
Why?
|
| Middle Aged | 11 | 2021 | 213390 | 0.070 |
Why?
|
| Blood Glucose | 1 | 2020 | 6254 | 0.070 |
Why?
|
| Age Factors | 3 | 2019 | 18373 | 0.070 |
Why?
|
| Prognosis | 2 | 2015 | 29060 | 0.060 |
Why?
|
| Anxiety | 1 | 2019 | 4293 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 7182 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 5388 | 0.060 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2001 | 4266 | 0.060 |
Why?
|
| Depression | 1 | 2023 | 7759 | 0.060 |
Why?
|
| Young Adult | 6 | 2021 | 56429 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 5692 | 0.050 |
Why?
|
| Prevalence | 2 | 2019 | 15221 | 0.050 |
Why?
|
| Calcium | 1 | 2015 | 5755 | 0.050 |
Why?
|
| Biosensing Techniques | 1 | 2008 | 668 | 0.050 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2008 | 1115 | 0.050 |
Why?
|
| Adolescent | 6 | 2021 | 85779 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 11031 | 0.050 |
Why?
|
| Vietnam | 1 | 2001 | 408 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2008 | 2076 | 0.050 |
Why?
|
| Calcifediol | 1 | 2021 | 166 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2001 | 17446 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 6896 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2001 | 977 | 0.040 |
Why?
|
| Keratinocytes | 1 | 2022 | 799 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2021 | 63107 | 0.040 |
Why?
|
| Obesity | 1 | 2020 | 12746 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2001 | 1005 | 0.040 |
Why?
|
| Glucose Tolerance Test | 1 | 2020 | 1151 | 0.040 |
Why?
|
| Quality of Life | 1 | 2019 | 12802 | 0.040 |
Why?
|
| Risk | 2 | 2020 | 9688 | 0.040 |
Why?
|
| Nicotine | 1 | 2022 | 681 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2008 | 3084 | 0.040 |
Why?
|
| Watchful Waiting | 1 | 2021 | 492 | 0.030 |
Why?
|
| Nanoparticles | 1 | 2008 | 1905 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 15160 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 9955 | 0.030 |
Why?
|
| Mutation | 1 | 2020 | 29786 | 0.030 |
Why?
|
| England | 1 | 2016 | 522 | 0.030 |
Why?
|
| Smoking | 2 | 2022 | 8987 | 0.030 |
Why?
|
| Fasting | 1 | 2020 | 1592 | 0.030 |
Why?
|
| Estrogens | 1 | 2021 | 1566 | 0.030 |
Why?
|
| Pregnancy | 3 | 2022 | 29144 | 0.030 |
Why?
|
| Focus Groups | 1 | 2019 | 1321 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 25039 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2001 | 2715 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 10943 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 1656 | 0.030 |
Why?
|
| Risk Factors | 2 | 2015 | 72296 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2019 | 2539 | 0.030 |
Why?
|
| United States | 2 | 2015 | 69872 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2017 | 2618 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 4185 | 0.020 |
Why?
|
| Ligands | 1 | 2018 | 3282 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2001 | 3493 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2019 | 77460 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2019 | 2682 | 0.020 |
Why?
|
| Rats | 2 | 2022 | 24252 | 0.020 |
Why?
|
| Overweight | 1 | 2020 | 2371 | 0.020 |
Why?
|
| Pain | 1 | 2022 | 4988 | 0.020 |
Why?
|
| Pigment Epithelium of Eye | 1 | 2008 | 220 | 0.020 |
Why?
|
| Child | 1 | 2015 | 77709 | 0.020 |
Why?
|
| Response Elements | 1 | 2008 | 312 | 0.020 |
Why?
|
| Rats, Inbred Lew | 1 | 2008 | 1162 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2001 | 5101 | 0.020 |
Why?
|
| Health Status | 1 | 2019 | 4034 | 0.020 |
Why?
|
| Cognition | 1 | 2023 | 6770 | 0.020 |
Why?
|
| Registries | 1 | 2001 | 8091 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 7914 | 0.020 |
Why?
|
| Cell Line | 1 | 2018 | 16000 | 0.010 |
Why?
|
| Phenotype | 1 | 2001 | 16367 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2008 | 1225 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2020 | 12721 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2008 | 1970 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 5135 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 5534 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2023 | 57776 | 0.010 |
Why?
|
| Glucose | 1 | 2008 | 4398 | 0.010 |
Why?
|
| Mitochondria | 1 | 2008 | 3514 | 0.010 |
Why?
|
| Animals | 2 | 2022 | 168768 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2008 | 19233 | 0.010 |
Why?
|